Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Terminated 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 3Tumor-Agnostic 1Thoracic 1Head & Neck 1Gastrointestinal 1Breast 1

Conditions

Weight Loss 1Pancreatic Neoplasms 1Lung Neoplasms 1Cachexia 1Body Weight 1Anorexia 1

Interventions

Gemcitabine 302Fluorouracil 296Oxaliplatin 269Bevacizumab 267Capecitabine 233Leucovorin 229pembrolizumab 215Irinotecan 185Cisplatin 142Cetuximab 142Nivolumab 131Paclitaxel 117130-nm albumin-bound paclitaxel 117Sorafenib 86Albumin-Bound Paclitaxel 75Docetaxel 65regorafenib 64atezolizumab 64IFL protocol 61Folfox protocol 61Trastuzumab 55Panitumumab 47durvalumab 46Ramucirumab 43Injections 43Sunitinib 41Drug Therapy 41Carboplatin 40trifluridine tipiracil drug combination 38lenvatinib 38

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Megestrol Acetate × Gastrointestinal × Clear all
NCT00637728 2016-06-23

Treatment of Cancer-anorexia Using Megestrol Acetate Concentrated Suspension in Lung or Pancreatic Cancer Patients

Par Pharmaceutical, Inc.

Phase 3 Terminated
5 enrolled 8 charts
GastrointestinalThoracic

Anorexia, Body Weight, Cachexia, Lung Neoplasms, Pancreatic Neoplasms, Weight Loss

Data powered by HemOnc (CC BY 4.0) Colophon âš¡